Genetic Testing Market (2023-2030)

Genetic testing encompasses the examination of chromosomes, proteins, and specific metabolites to identify heritable disease-related genotypes, mutations, phenotypes, or karyotypes for clinical purposes. Applications include prenatal testing, predictive and presymptomatic testing, diagnostic testing, carrier testing, and preimplantation testing, often employing high-throughput sequencing technologies such as next-generation sequencing.

A growing number of tests are being developed to analyze multiple genes that may increase or decrease a person’s risk of diseases, such as cancer or diabetes. Such tests and other applications of genomic technologies have the potential to help prevent common diseases and improve the health of individuals and populations.

The growth of this market is mainly driven by government initiatives promoting genetic testing, the increasing prevalence of genetic disorders, a growing need for the early detection & prevention of diseases, the increasing applications of genetic testing in oncology, and the decreasing costs of sequencing procedures. However, the high cost of genetic testing in low-income countries and the social and ethical implications of genetic testing restrain the growth of the genetic testing market.

The growing potential of direct-to-consumer genetic testing and the emerging field of genetic counseling are expected to create growth opportunities for the players operating in this market. However, the low chances of positive, actionable mutations and concerns regarding the security & privacy of genetic data are major challenges to market growth.

The outbreak of COVID-19 in March 2020 was a public health crisis and led to nationwide lockdowns and restrictions in many countries worldwide. The majority of the health services & resources were diverted to prioritizing COVID-19. Similarly, laboratory resources and skilled personnel for genetic and genomic testing were directed toward fighting the COVID-19 pandemic. The volume of genetic testing decreased during the pandemic due to growing cases of infections due to its variants like Delta and Omicron. The pandemic negatively impacted the demand for genetic testing due to the prioritization of healthcare resources for COVID-19.

The stringent lockdowns and restrictions led to supply chain disruption leading to delays in delivering the laboratory reagents and equipment. These factors impacted the growth of the market to a certain extent; however, the market is gaining traction as the situation is normalizing. Countries around the world enhanced their genomics capabilities during the pandemic to identify the spread of the virus. The COVID-19 pandemic has increased the adoption of advanced technologies such as NGS for various applications, including epidemiology, metagenomic analysis, and diagnostics. The widespread adoption of enhanced genomic technologies by many countries around the world offers a great opportunity for the genetic testing market.

Cancer is a genome disease, and major strides have been made in understanding and treating this heterogeneous collection of diseases. This comprises the initial identification of oncogenes and tumor suppressor genes for the development of the first generation of targeted therapies, culminating in the full annotation of the genomic landscape of the most common cancer types.

The global prevalence of cancer is expected to increase from 19.2 million new cases in 2020 to 24.0 million new cases in 2030, as per International Agency for Research on Cancer. Also, the mortalities from cancer are expected to increase from 9.9 million deaths in 2020 to 12.9 million deaths in 2030. Oncology biomarkers can provide affordable, reliable, accurate, non-invasive, and sensitive information to help effectively manage cancer. Early cancer detection can lead to positive results.

Sequencing technologies like NGS are increasingly used for genetic profiling in targeted cancer therapy applications due to the decreasing costs and turnaround time of NGS, improvements in bioinformatics analyses, and the harmonization of the knowledge base to facilitate the clinical interpretation of genetic results.

Direct-to-consumer genetic testing (DCGT) allows individuals to gain a deeper understanding of their genetic information without involving their physicians. This area is growing majorly due to consumers’ increasing awareness about the links between genetics and diseases, enhancing the evolution of patients' health, and precision medicine designed around individual genetic profiles. For accurate genetic testing, companies are working to improve the detection of carrier status and ease of consumer use.

In recent years, the number of DTC genetic tests performed has increased significantly and is expected to show strong growth in the future. Moreover, growing consumer use and subsequent follow-up with healthcare providers and insurers can be further anticipated to propel the growth of DTC genetic testing.